MedTrace Logo

Inhale and Exhale Breath Holds to Improve the Radiation Therapy Accuracy in People With Upper Abdominal Cancers

NCT07594691 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-05-26

No results posted yet for this study

Summary

This is a prospective quality improvement study. The INEX RT P study will prospectively evaluate INEX RT R that optimizes radiation dose delivery to the target while minimizing dose to critical organs at risk (OAR) by treating patients with different phases of breath hold (inhale and exhale) during the same course of SBRT. 15 patients with abdominal cancer whom are expected to achieve a dosimetric advantage from this technique due to OAR proximity to target will be treated using INEX RT. Investigators hypothesize increasing the dose to the RT target by at least 10% while simultaneously decreasing or maintaining dose to adjacent critical OARs when using a combination of breath hold positions to purposefully vary the position of OARs during different fractions of the same treatment course, when compared to RT treatments planned on a single breath hold phase alone (present standard of care).

Conditions

  • Abdominal Cancer

Interventions

DIAGNOSTIC_TEST

Simulation and treatment imaging

Obtain inhale and exhale breath hold images planned to split radiation delivery between inhale and exhale breath hold phases. For radiotherapy courses with an odd number of fractions, the phase of breath hold with higher reproducibility or anatomic advantage will be used for the additional fraction of radiotherapy. If during the treatment planning the investigators determine that the patients will benefit from the multiple breath holds technique, the patients will be treated using the composite breath hold plan. Additional one or two cone beam CTs will be obtained on treatment days for all patients using the inhale and exhale breath hold technique.

Sponsors & Collaborators

  • University Health Network, Toronto

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-20
Primary Completion
2027-05-30
Completion
2028-01-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07594691 on ClinicalTrials.gov